News

AFFiRiS announced a realignment of its development strategy on neurodegenerative diseases, a core area of expertise of the company. Affiris will now...

Read more

The wait has come to an end – the Phenaris Transporter Models are officially available for purchase! These computational models can predict...

Read more

Scientists from the labs of Alipasha Vaziri at The Rockefeller University and the Research Institute of Molecular Pathology (IMP), together with...

Read more

Valneva announced today that the U.S. government Department of Defense (DoD) has exercised an option to purchase 80,000 additional doses of its...

Read more

Vienna Drosophila Resource Center's contribution to the genome research worldwide has been acknowledged in the Austria-wide newspaper Die Presse.

Read more

Valneva today announced a further expansion of its global commercial infrastructure with the opening of a French commercial office in Lyon.

Read more

Read more

Valneva announced today that an End Of Phase 2 meeting has been scheduled with the U.S. Food and Drug Administration on February 24, 2020 for its...

Read more

Max Perutz Labs group leader Shotaro Otsuka was awarded a “Life Science” grant by the Vienna Science and Technology Fund (WWTF). This project is a...

Read more

Researchers from IMBA – Institute of Molecular Biotechnology of the Austrian Academy of Sciences – are granted funding for two projects from the...

Read more

Valneva SE confirmed today that it has completed the delisting of its ordinary and preferred shares from the Vienna Stock Exchange (“VSE”). Valneva...

Read more

Phenaris announced another big success accomplished with ToxPHACTS shortly before the end of the year, as they won won the 3rd place at the i2b...

Read more

All organisms need to adjust their energy consumption in response to internal and external signals, thereby allocating energy to growth, reproduction...

Read more